Midatech operates an in-house nanoparticle manufacturing facility, which is believed to be the first licensed API cGMP facility of its kind in Europe. This state-of-the-art facility based in Bilbao, Spain, aids in the rapid execution of projects, control of manufacturing quality and supply of all aspects of Midatech’s GNP platform, thus avoiding reliance on external manufacturing partners.
The site has capacity for manufacturing sufficient materials for clinical trials and is fully licensed by the Spanish Medicines Agency for European compliance. The facility underwent a €800,000 upgrade in September 2014 to enable the production of sterile material for use in human clinical trials and initial phase manufacturing of licensed product.
Also in 2014, an international consortium led by Midatech was selected to receive a €7.9 million Horizon 2020 European Union “NanoFacturing” grant to fund the manufacturing scale-up of clinical-grade therapeutics based on its GNP drug conjugate technology and other nanopharmaceuticals, for use in clinical trials and in preparation for commercial production and supply. Midatech is also able to leverage this facility to manufacture for other non-competing nanomedicine businesses, representing additional revenue generating opportunities. The Horizon 2020 grant submission was supported by Eli Lilly.